Lower Oesophagus Cancer, Oesophageal Junction Cancer, Stomach Neoplasms
Conditions
Keywords
medical oncology, chemotherapy optimization, dose density
Brief summary
If surgery remains the main treatment for gastric cancer without distant metastases; perioperative-chemotherapy increased the likelihood of progression free survival. Perioperative chemotherapy appears to have many advantages : to reduce the tumor volume, to improve the R0 resection rate, and to act on micro-metastases. Therefore, peri-operative chemotherapy combining cisplatin, epirubicin and 5-Fluorouracile is a validated strategy to treat gastric cancer. However, several pitfalls remained. Particularly, only 42% of patients could received post-chemotherapy, due to post-operative complications and toxicities. To overcome this limitation, the investigators will conduct a phase II clinical trial assessing the clinical interest of a dose-dense preoperative chemotherapy combining cisplatin (P), epirubicin (E) and paclitaxel (T). The increasing evidence of taxane's role in gastric cancer treatment, as well as the biological synergisms reported in paclitaxel/cisplatin and paclitaxel/epirubicin combinations, sustain the development of dose density based on PET combination in gastric carcinoma. The aim of the IPEC-GC study is to evaluate the effectiveness of this PET preoperative regimen
Detailed description
The IPEC-GC study is a proof-of-concept study evaluating the efficacy and feasibility of PET regimen in 61 patients with lower oesophagus, oesophagus junction or gastric carcinoma. Preoperative chemotherapy include eight weekly preoperative cycles of cisplatin (30mg/m2), epirubicin (50 mg/m2) and paclitaxel (90 mg/m2)with a break of one week without chemotherapy between cycle 4 and 5. Surgery is performed within 4-6 weeks after the end of the last cycle of chemotherapy. Primary endpoint of this trial is the curative resection rate (=R0). R0 must be higher than the 79% achieved in previous published studies. Response rate, histologic response rate (Becker score), progression-free survival, overall survival, impact of complete response in survival and dose-density are secondary endpoints. For an ancillary study, tumors (biopsies and operative specimens) and sera will be collected to identify biomarkers correlated with treatment efficacy. This study is carried out by the Besançon University Hospital and were approved by the independent Est-II ethics committee and by the French National Authority for Health: AFSSAPS.
Interventions
DRUGEpirubicin
8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
DRUGCisplatin
8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
DRUGPaclitaxel
8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
PROCEDUREgastric surgery
surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
: * Age \> 18 and \< 70 years (male and female) * surgical resectability * ECOG performance status ≤ 1 * ASA score \< 3 (appreciation by a surgeon) * BMI \< 30 if an upper oesogastrectomy is required * no previous cytotoxic chemotherapy * ejection fraction \> 50% in echocardiography before start of therapy * written informed consent Non-inclusion criteria : * distant metastases or infiltration of adjacent structures or organs and all primarily not resectable stages * relapse * hypersensitivity against Paclitaxel, Epirubicin or Cisplatin * malignant secondary disease, dated back \< 5 years (exception: in situ carcinoma of the cervix uteri, adequately treated skin basal cell carcinoma) * peripheral polyneuropathy * diabetes complicated by coronary artery disease or vasculopathy * Severe respiratory insufficiency * patient with weight loss \> 10% * pregnancy or lactation * inclusion in another trial * patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| curative resection rate | an expected average of 4 weeks after surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| response rate | between 2 and 4 weeks after the end of the last cycle of chemotherapy | Response rate will be evaluated using RECIST v1.1 criteria (Response Evaluation Criteria in Solid Tumors ; Eisenhauer et al, 2009) by a CT-scan done between 2 and 4 weeks after the end of the last cycle to verify the absence of local or distant progression before surgery |
| histologic response rate | an expected average of 4 weeks after surgery | Histologic response rate will be determined by the pathologist laboratory on operative specimens using Becker's score (Becker et al, 2003) to measure effects of neoadjuvant chemotherapy on gastric cancer. |
| tolerance of the therapeutic association | 1 week after each chemotherapy cycle | Toxicities will be evaluated using Common Terminology Criteria for Adverse Events version 4. |
| progression free survival | from date to initiation of chemotherapy until the date of first documented progression (within 5 years after surgery) | — |
| global survival | from date to initiation of chemotherapy until the date of death for any cause (within 5 years after surgery) | — |
Countries
France
Outcome results
None listed